Loading…
Senti Biosciences Holdings, Inc. is projected to rise to $1.01 by 2027, a +1% move from its current price of $1.00. SNTI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9624 | $0.9996 | $1.04 | -0.04% |
| Jul 14 | $0.9471 | $0.9991 | $1.05 | -0.09% |
| Jul 15 | $0.9353 | $0.9987 | $1.07 | -0.13% |
| Jul 16 | $0.9255 | $0.9982 | $1.08 | -0.18% |
| Jul 17 | $0.9168 | $0.9978 | $1.09 | -0.22% |
| Jul 18 | $0.9091 | $0.9973 | $1.09 | -0.27% |
| Jul 19 | $0.9019 | $0.9969 | $1.10 | -0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9019 | $0.9969 | $1.10 | -0.31% |
| Week 2 | $0.8626 | $0.9938 | $1.14 | -0.62% |
| Week 3 | $0.833 | $0.9907 | $1.18 | -0.93% |
| Week 4 | $0.8084 | $0.9876 | $1.21 | -1.24% |
| Week 5 | $0.7871 | $0.9845 | $1.23 | -1.55% |
| Week 6 | $0.7681 | $0.9815 | $1.25 | -1.85% |
| Week 7 | $0.7508 | $0.9784 | $1.28 | -2.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Senti Biosciences Holdings, Inc. is a clinical stage biotechnology company that develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
In addition to SENTI-202, the company’s pipeline includes the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
SNTI trades at $1.00 with a market capitalization of $31.14M, and it is ranked 4762 by market cap.
The near-term technical backdrop is neutral, with RSI at 50 and moving averages showing SMA50 at $0.99 and SMA200 at $1.24. These levels help frame a price around the current level as investors weigh fundamentals against market action.
The 30-day price range runs from $0.7765 to $1.29, and the stock carries notable volatility. Annualized volatility stands at 70%, underscoring the risk/return profile typical of smaller biotechs with early-stage programs.
Forecasts indicate a bullish trajectory over the longer term, with average prices moving higher across several checkpoints and strength emerging later in the decade. Key anchors include a 2026 avg of $1.00, climbing toward $1.56 by 2030 and culminating near $4.73 in 2050, with max values rising to $10.06 in 2050 and ROIs scaling to as high as 372.9%.
A major floor 22.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 11.0% above — a clean break opens room to run.
A major ceiling 21.9% above — clearing it would confirm fresh momentum.
Key SNTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.03 | Sell | $1.03 | Sell |
| MA 10 | $1.06 | Sell | $1.04 | Sell |
| MA 20 | $1.02 | Sell | $1.02 | Sell |
| MA 50 | $0.9915 | Buy | $1.00 | Sell |
| MA 100 | $0.9644 | Buy | $1.04 | Sell |
| MA 200 | $1.24 | Sell | $1.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.51 | Neutral |
| Stoch RSI (14) | 35.38 | Neutral |
| CCI (20) | 14.31 | Neutral |
| Williams %R (14) | -43.24 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 11.35 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 56.76 | Neutral |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 44.54 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 1.00 | Sell |
| ADX (14) | 9.34 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is neutral overall, supported by a Neutral sentiment and an RSI of 50. The stock’s price action sits near the SMA50 of $0.99, with the SMA200 at $1.24, framing near-term momentum.
Support sits at $0.906 and resistance at $1.11, creating a defined trading envelope around the current price. The 30-day price range spans from $0.7765 to $1.29, highlighting modest upside potential against downside risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.772 | $1.00 | $1.27 | 0% | Neutral | |
| $0.7743 | $1.01 | $1.41 | +1% | Neutral | |
| $0.7926 | $1.08 | $1.57 | +8% | Neutral | |
| $0.9072 | $1.27 | $1.93 | +27% | Bullish | |
| $1.10 | $1.59 | $2.49 | +59% | Bullish | |
| $1.05 | $1.57 | $2.52 | +57% | Bullish | |
| $0.9874 | $1.51 | $2.49 | +51% | Bullish | |
| $1.01 | $1.58 | $2.66 | +58% | Bullish | |
| $0.9805 | $1.57 | $2.70 | +57% | Bullish | |
| $1.06 | $1.74 | $3.05 | +74% | Bullish | |
| $1.27 | $2.31 | $4.38 | +131% | Bullish | |
| $2.25 | $4.98 | $10.53 | +398% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.772 | $1.00 | $1.22 | +0.00% |
| August 2026 | $0.8303 | $0.9905 | $1.22 | -0.95% |
| September 2026 | $0.7971 | $0.9602 | $1.20 | -3.06% |
| October 2026 | $0.8207 | $0.9971 | $1.26 | +3.84% |
| November 2026 | $0.8353 | $1.02 | $1.31 | +2.50% |
| December 2026 | $0.7952 | $0.9795 | $1.27 | -4.16% |
Click any year to see its month-by-month SNTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNTI price prediction for 2026 points to an average of $1.00 (low $0.772, high $1.27) — a potential gain of 0% on today's $1.00. A consolidation phase looks the most probable path here.
In 2027, SNTI is projected to trade between $0.7743 and $1.41, averaging $1.01 — a potential gain of +1% from today's $1.00. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
Senti Biosciences Holdings, Inc.'s 2028 outlook centres on $1.08, within a $0.7926 to $1.57 range. That is up +7% on the projected 2027 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, SNTI could reach as high as $1.93, with a base case around $1.27 and support toward $0.9072 — roughly +27% from $1.00. Momentum favours further upside here.
Expect SNTI to range from $1.10 to $2.49 through 2030. The $1.59 average target implies a +59% move from current prices. That is up +25% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The SNTI price prediction for 2031 points to an average of $1.57 (low $1.05, high $2.52) — a potential gain of +57% on today's $1.00. Momentum favours further upside here.
In 2032, SNTI is projected to trade between $0.9874 and $2.49, averaging $1.51 — a potential gain of +51% from today's $1.00. That is -4% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Senti Biosciences Holdings, Inc.'s 2033 outlook centres on $1.58, within a $1.01 to $2.66 range. That is up +5% on the projected 2032 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2034, SNTI could reach as high as $2.70, with a base case around $1.57 and support toward $0.9805 — roughly +57% from $1.00. Buyers look set to stay in control over this stretch.
Expect SNTI to range from $1.06 to $3.05 through 2035. The $1.74 average target implies a +74% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The SNTI price prediction for 2040 points to an average of $2.31 (low $1.27, high $4.38) — a potential gain of +131% on today's $1.00. Buyers look set to stay in control over this stretch.
In 2050, SNTI is projected to trade between $2.25 and $10.53, averaging $4.98 — a potential gain of +398% from today's $1.00. That is up +115% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SNTI today (≈ 1,000 SNTI) could be worth
$4,980.53
+$3,980.53 (+398%) by 2050 · US Dollar
Based on the average projected SNTI price of $4.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNTIwould be worth at today's price.
$1,000 invested in SNTI on Jul 10, 2025 (≈ 431.034495 SNTI) would be worth
$431.03
-$568.97 (-56.9%) today · 0.43× · US Dollar
Based on a SNTI entry price of $2.32 vs. today's $1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.07 | $934.58 | -6.5% |
| 1 month ago | $0.96 | $1,041.67 | +4.2% |
| 3 months ago | $0.873 | $1,145.48 | +14.5% |
| 6 months ago | $1.12 | $892.86 | -10.7% |
| 1 year ago | $2.32 | $431.03 | -56.9% |
| All time (5.0y) ago | $98.6 | $10.14 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNTI forecast.
Our base-case forecast reaches $2.00 around 2040.
Implied market cap at $2.00: $62.29M
The multi-year forecast envisions a bullish path beginning in 2029, with 2029 avg $1.24 and 2030 avg $1.56, followed by sustained upside through 2035 ($1.66 avg) and into 2040 ($2.21 avg) before reaching an average of $4.73 in 2050. Max price projections extend to $2.45 in 2030, $2.60 in 2033, $4.22 in 2040, and $10.06 in 2050. ROI climbs from 0% in 2026 to 55.6% in 2030, then to 372.9% by 2050, with sentiment labeled Bullish in the later years.
These trajectories reflect estimates rather than guarantees and assume the continued evolution of clinical programs and regulatory pathways. The long-term picture is shaped by higher price expectations and volatility, with annualized volatility listed at 70% as a risk context for the stock’s swing potential.
Tap a question to reveal the answer.
In 2030 the avg price is $1.56, with a min of $1.07 and a max of $2.45. The forecast also cites a 55.6% ROI and a Bullish sentiment for that year.
The forecast shows a Bullish sentiment from 2029 onward, with rising averages (e.g., 2029 avg $1.24, 2030 avg $1.56) and returns up to 372.9% by 2050. These are estimates, not guarantees, and the stock carries notable volatility.
The 2030 max is $2.45, but the 2033 max is $2.60, suggesting the price could exceed $2.50 by 2033 if the trajectory holds. These are projection values, not certainties.
The current price is $1.00 and the market cap is $31.14M.
Annualized volatility is 70%.
Senti Biosciences Holdings, Inc. Community Discussion
0Share your Senti Biosciences Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.